The global plasma fractionation market is set to expand significantly, with a projected CAGR of 6.7% from 2023 to 2031, foreseeing sales revenue of USD 42.6 billion by 2031. Key market players include CSL Behring, Grifols, Takeda Pharmaceutical, and Octapharma, with emerging companies like Kedrion Biopharma and China Biologic also making notable strides. Integration of technologies such as AI and data analytics is bolstering operational efficiency and product safety, while supply chain optimization efforts and cost reduction strategies are heightening market competitiveness.

Plasma Fractionation Market Growth